内皮功能障碍和动脉粥样硬化:关注新的治疗方法。

Alexandros Briasoulis, Dimitris Tousoulis, Emmanuel S Androulakis, Nikolaos Papageorgiou, George Latsios, Christodoulos Stefanadis
{"title":"内皮功能障碍和动脉粥样硬化:关注新的治疗方法。","authors":"Alexandros Briasoulis,&nbsp;Dimitris Tousoulis,&nbsp;Emmanuel S Androulakis,&nbsp;Nikolaos Papageorgiou,&nbsp;George Latsios,&nbsp;Christodoulos Stefanadis","doi":"10.2174/157489012799362386","DOIUrl":null,"url":null,"abstract":"<p><p>Endothelial dysfunction reflected by reduced nitric oxide (NO) availability is certainly the causative factor or promoting mechanism of atherosclerosis. It is necessary to detect endothelial dysfunction at an early stage using appropriate methods, and to choose a treatment for the recovery of endothelial function. There are nonpharmacological and pharmacological therapies to attain endothelial repair. The latter includes the use of renin-angiotensin system inhibitors, statins, erythropoietin, tetrahydrobiopterin, and antioxidants. The pharmacologic therapies are intended to increase NO synthase activity and NO release, inhibit NO degradation, and enhance the activity of endothelial progenitor cells. This article reviews the current knowledge of the pathophysiological events contributing to endothelial dysfunction as well as several established and novel treatment options to reverse those changes along with the discussion of recent patents.</p>","PeriodicalId":20905,"journal":{"name":"Recent patents on cardiovascular drug discovery","volume":"7 1","pages":"21-32"},"PeriodicalIF":0.0000,"publicationDate":"2012-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/157489012799362386","citationCount":"42","resultStr":"{\"title\":\"Endothelial dysfunction and atherosclerosis: focus on novel therapeutic approaches.\",\"authors\":\"Alexandros Briasoulis,&nbsp;Dimitris Tousoulis,&nbsp;Emmanuel S Androulakis,&nbsp;Nikolaos Papageorgiou,&nbsp;George Latsios,&nbsp;Christodoulos Stefanadis\",\"doi\":\"10.2174/157489012799362386\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Endothelial dysfunction reflected by reduced nitric oxide (NO) availability is certainly the causative factor or promoting mechanism of atherosclerosis. It is necessary to detect endothelial dysfunction at an early stage using appropriate methods, and to choose a treatment for the recovery of endothelial function. There are nonpharmacological and pharmacological therapies to attain endothelial repair. The latter includes the use of renin-angiotensin system inhibitors, statins, erythropoietin, tetrahydrobiopterin, and antioxidants. The pharmacologic therapies are intended to increase NO synthase activity and NO release, inhibit NO degradation, and enhance the activity of endothelial progenitor cells. This article reviews the current knowledge of the pathophysiological events contributing to endothelial dysfunction as well as several established and novel treatment options to reverse those changes along with the discussion of recent patents.</p>\",\"PeriodicalId\":20905,\"journal\":{\"name\":\"Recent patents on cardiovascular drug discovery\",\"volume\":\"7 1\",\"pages\":\"21-32\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2174/157489012799362386\",\"citationCount\":\"42\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Recent patents on cardiovascular drug discovery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/157489012799362386\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent patents on cardiovascular drug discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/157489012799362386","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 42

摘要

一氧化氮(NO)可得性降低所反映的内皮功能障碍无疑是动脉粥样硬化的诱因或促进机制。早期采用合适的方法检测内皮功能障碍,选择合适的治疗方法恢复内皮功能是很有必要的。有非药物和药物治疗达到内皮修复。后者包括使用肾素-血管紧张素系统抑制剂、他汀类药物、促红细胞生成素、四氢生物蝶呤和抗氧化剂。药物治疗旨在增加NO合成酶活性和NO释放,抑制NO降解,增强内皮祖细胞的活性。本文回顾了导致内皮功能障碍的病理生理事件的当前知识,以及一些已建立的和新的治疗方案,以逆转这些变化,并讨论了最近的专利。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Endothelial dysfunction and atherosclerosis: focus on novel therapeutic approaches.

Endothelial dysfunction reflected by reduced nitric oxide (NO) availability is certainly the causative factor or promoting mechanism of atherosclerosis. It is necessary to detect endothelial dysfunction at an early stage using appropriate methods, and to choose a treatment for the recovery of endothelial function. There are nonpharmacological and pharmacological therapies to attain endothelial repair. The latter includes the use of renin-angiotensin system inhibitors, statins, erythropoietin, tetrahydrobiopterin, and antioxidants. The pharmacologic therapies are intended to increase NO synthase activity and NO release, inhibit NO degradation, and enhance the activity of endothelial progenitor cells. This article reviews the current knowledge of the pathophysiological events contributing to endothelial dysfunction as well as several established and novel treatment options to reverse those changes along with the discussion of recent patents.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信